Capítulo 8. 3. Agentes inmunosupresores en el transplante de órganos sólidos

Bibliografía
 

1.- Gómez de la Concha E, Angulo Barturen I. Sistema HLA y presentación del antígeno. En: Diaz Rubio M y Espinos D, ed. Tratado de Medicina Interna. Madrid, Editorial Médica Panamericana, 1996; 132-139
2.- Kreisler García JM. Inmunidad y trasplante. Medicine 1997; 7 : 2294-2302. 
3.- Kuby J. Immunology. W H Freeman and Company, New York 1992.
4.- Gómez de la Concha E, Medina Peñafiel Mª T, Boimorto Pérez. El sistema inmunitario. En: Diaz Rubio M y Espinos D, ed. Tratado de Medicina Interna. Madrid, Editorial Médica Panamericana, 1996; 115-125.
5.- Andrade W, Fernández-Miguel G, Sanz E. Distinta visión del universo antigénico por las células T, NK y B. Medicine 1997; 7 : 2187-2192.
6.- Fernández-Miguel G, Andrade W, Sanz E. Células T: mecanismos de reconocimiento antigénico y ontogenia. Medicine 1997; 7 : 2193-2199.
7.- Manzano Espinosa L, Prieto Martín A, Reyes Martín E, Alvarez-Mon Soto M. Celulas natural killer. Medicine 1997; 7 :  224-2228.
8.- Reyes Martín E, Hernández Fuentes MP, Prieto Martín A, Alvarez-Mon Soto M. Células fagocíticas. Tipos, mecanismo y función. Medicine 1997; 7 : 2236-2240.
9.- Prieto Martín A, Reyes Martín E, Pérez Gómez A, Alvarez-Mon Soto M. Moléculas coestimuladoras tanto solubles como de membrana implicadas en la presentación antigénica y la respuesta inmune. Medicine 1997;  7 : 2255-2262.
10.- Criado García O, Rodríguez de Córdoba S. Sistema del complemento, sus receptores y proteinas reguladoras. Medicine 1997; 7 :  2229-2235.
11.- Frenette PS, Wagner DD. Adhesion Molecules - Part I. N Eng J Med 1996; 334: 1526-1529.
12.- Frenette PS, Wagner DD. Adhesion Molecules - Part II: Blood vessels and blood cells. N Eng J Med 1996; 335: 43-45.
13.- Hayes JM. The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation. J Urol 1993; 149: 437-448.
14.- Simmons RL, Ildstad ST, Smith CR, Reemtsma K, Najarian JS. Trasplantes. En: Schwartz SI, Shires GT, Spencer FC, Eds. Principios de Cirugía. México, Panamericana-McGraw Hill, 1994; 389-471.
15.- Goldman M, Abramowicz D, Alegre ML. Acute allograft rejection: immunobiology and therapeutics strategies. En: Vincent JL, ed. Year Book of Intensive Care and Emergency Medicine. Berlin, Springer Verlag 1992; 585-593.
16.- Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
17.- Suthathiran M, Morris RE, Strom TB.  Immunosuppresants: cellular and molecular mechanisms of action.  Am J Kidney Dis, 1996; 28: 159-172.
18.- Calne RY, Rolles K, Thiru S, McMaster P, Craddock GN, Azis S, et al.  Cyclosporin A initially as the only immunosuppressant in 34 patients of cadaveric organs: 32 kidneys, 2 pancreas, and 2 livers.  Lancet, 1979; ii: 1033-1036.
19.- European Multicentre trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial.  Lancet, 1983; ii: 2986-2989.
20.- Canadian Multicentre Transplant Study Group.  A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med, 1983; 309: 809-815.
21.- Tredger JM for the Unted Kingdom Neoral Pilot Study Group. Using cyclosporine Neoral immediately after liver transplantation.  Ther Drug Monit, 1995; 17: 638-641.
22.- Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K.  Pharmacokinetics and tolerability of microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation.  Transplantation, 1994; 57: 1178-1182.
23.- Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K.  Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients.  Ther Drug Monit, 1994; 16: 232-237.
24.- Mueller EA, Kallay Z, Kovark JM, Richard F, Wiesinger O, Schmidt K, Scheele J.  Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients.  Transplantation, 1995; 60: 515-517.
25.- Aumente MD, Panadero MD, Caraballo MD, Pozo JC, Pérez JL.  Pharmacokinetic profile of cyclosporine neoral in liver transplant recipients with external biliary diversion.  Pharmacy World Sci, 1995; 17: Suppl J, J11.
26.- Neiderberger W, Le Maire G, Maurer K, Nussbaumer K, Wagner D.  Distribution and binding of cyclosporine in blood and tissues.  Transplant Proc, 1983; 15: 2419-2422.
27.- Cuervas-Mons V, Barrios C, Garrido A.  Medicamentos inmunosupresores.  En: Cuervas-Mons V, Ed. Trasplante Hepático. Barcelona, Ediciones Mayo,  1993;  85-106.
28.- McMaster P, Mirza DF.  Optimal use of cyclosporin A in liver transplantation.  Transplant Proc, 1994; 26: 2662-2664.
29.- de Groen PC.  Cyclosporine and the liver: how one affects the other.  Transplant Proc, 1990; 22: 1197-1202.
30.- Rossi SJ, Schroeder TJ, Hariharan S.  Prevention and management of the adverse effects associated with immunosuppresive therapy.  Drug Saf, 1993; 9: 104-131.
31.- Varghese Z, Chan MK, Steele LW, Sweeny P, Fernando ON, Moorhead JF.  How to measure cyclosporin.  Lancet, 1984; i: 1407.
32.- Kelly PA, Burckart GJ, Venkataramanan R.  Tacrolimus: a new immunosuppressive agent.  Am J Health-Syst Pharm, 1995; 52: 1521-1535.
33.- Starzl TE, Todo S, Fung J, Demetris AJ, Venkataremman R, Jain A.  FK 506 for liver, kidney, and pancreas transplantation. Lancet, 1989; ii: 1000-1004.
34.- Fung JJ, Todo S, Tzakis A. Conversion  from  cyclosporine to FK 506 in  liver allograft  recipients  with  cyclosporine-related complications.   Transplant Proc, 1990; 22: 6-12.
35.- Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, et al.  The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular refernce to the liver.  Transplantation, 1991; 52: 71-77.
36.- European FK506 Multicenter Liver Study Group.  Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograf rejection.  Lancet, 1994; 344: 423-428.
37.- The U.S. Multicenter FK-506 Liver Study group. A comparison of tacrolimus (FK-506) and cyclosporine for immunosuppresion in liver transplantation. N Engl J Med, 1994; 331: 1110-1115.
38.- Klintmalm GB.  Clinical use of FK 506 in liver transplantation.  Transplant Proce, 1996; 28: 974-976.
39.- Mueller AR, Platz KP, Bechstein WO, Schattenfroh N, Stoltenburg-Didingar G, Blumhardt G, Christie W, Neuhaus P.  Neurotoxicity after orthotopic liver transplantation. Transplantation, 1994; 58: 155-170.
40.- Porayko MK, Textor SC, Krom RAF, Hay JE, Gores GJ, Richards TM, et al.  Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantatation.  Mayo Clin Proc, 1994; 69: 105-111.
41.- Platz KP,    Mueller AR,  Blumhardt G,   Bachmann S,   Bechstein WO,    Kahl A,  Neuhaus P.   Nephrotoxicity following orthotopic liver transplantation.  Transplantation, 1994;  58: 170-178.
42.- Platz KP, Mueller AR, Blumhardt G, Bechstein WO, Neuhaus P.  Toxicity versus rejection - or why conversions between cyclosporine A and FK506 were performed after liver transplantation.  Clin Transplantation 1995; 9: 146-154.
43.- Burkhalter EL, Starzl TE, van Thiel DH.  Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone.  J Hepatology, 1994; 21: 572-577.
44.- Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Christe W, Hopf U, et al.  The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK 506?  Clin Transplantation, 1995; 9: 176-184.
45.- Nuño J, Cuervas-Mons V, Vicente E, Turrión V, Pereira F, Mora NP, et al.  Renal failure after liver transplantation: analysis of risk factors in 139 liver transplant patients.  Transplant Proc, 1995; 27: 2319-2320.
46.- Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC, et al. Systemic and renal hemodynamic differences between FK 506 and cyclosporine in liver transplant recipients.  Transplantation, 1993; 55: 1332-1339.
47.- Conte G, Dal Canton A, Sabbatini M, Napodano P, De Nicola L, Gigliotti G, et al.  Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects.  Kidney Int, 1989; 36: 1086-1092.
48.- Driscoll DF, Pinson CW, Jenkins RL, Bistrian BR.  Potential protective effects of furosemide against early renal injury in liver transplant patients receiving cyclosporine-A.  Crit Care Med, 1989; 17: 1341-1343.
49.- Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P.  Amelioration of experimental cyclosporine nephrotoxicity by calcium channel inhibition.  Transplantation, 1992; 54: 1103-1106.
50.- Dupont E, Wybran J, Toussaint C.  Glucocorticosteroids and organ transplantation.  Trasnplantation, 1984, 37: 331-335.
51.- Lewis GP, Jusko WJ, Burke CW, Graves L.  Prednisone side effects and serum protein levels.  Lancet, 1971; ii: 778-781.
52.- Frey FL.  Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients.  Kidney Int, 0991; 39: 1034-1050.
53.- Ohlman S, Lafolie P, Lindholm A, Liliemark J, Tyden G, Peterson C. Large interindividual variability in bioavailability of azathiprine in renal transplant patients.  Clin Transplantation, 1993; 7: 65-70.
54.- Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H.  Monitoring of azathioprine-induced immunosuppression with thiopurine metyltransferase activity in kidney transplant recipients.  Transplantation, 1995; 60: 639-642.
55.- Groth CG, Ohlman S, Gannedahl G, Ericzon BG.  New immunosuppressive drugs in transplantation.  Transplant Proc, 1993; 25: 2681-2683.
56.- Sollinger HW. Mycophenolate mofetil.  Kidney Int, 1995; 48 (Suppl 52): S14-S17.
57.- Allison AC, Eugui EM.  Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).  Clin Transplantation, 1996; 10: 77-84.
58.- European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
59.- Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation, 1995; 60: 225-232.
60.- Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, et al.  RS-61443 (mycophenolate mofetil): A multicenter study for refractory kidney transplant rejection.  Ann Surg, 1992; 216: 513-519.
61.- Haley CJ, Jaklistch A, McGowan B, Wieder-Bunger T, Kempe T, Alexander S, et al.  Feasibility of an EMIT assay for mycophenolic acid in plasma.  Ther Drug Monit, 1995; 17: 431.
62.- Freise CE, Hebert M, Osorio RW, Nikolai B, Lake JR, Kauffman RS et al.  Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc, 1993; 25: 1758-1759.
63.- Stepkowski SM, Kahan BD.  Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar.  Transplant Proc, 1993; 25 (suppl 2): 29-31.
64.- Mousson C, Tanter Y, Racadot E, Wijdenes J, Chalopin JM, Chevet D, et al.  Cd4 and CD25 monoclonal antibody cocktail in kidney transplant rejection prophylaxis: clinical results of a pilot study.  Transplant Proc, 1995; 27: 1727-1728.
65.- van Gelder T, Zietse R, Mulder AH, Yzermans JNM, Hesse CJ, Vaessen LMB, et al.  A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation, 1995; 60: 248-252.
66.- Wilde MI, Goa KL.  Muromonab CD3 a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs, 1996; 51: 865-894.
67.- Kreis H.  Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection.  Clin Transplant, 1993; 7: 431-446.
68.- Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.  N Engl J Med, 1990; 323: 1723-1728.
69.- McMaster P. Patient and graft survival in the European Multicentre Liver Study-FK506 vs cyclosporine A. Transpl Int 1994; 7 (Suppl.1): S32-S36.
70.- Shapiro R, Jordan ML, Scantlebury VP. Randomized Trial of FK506/prednisone vs FK506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant. Proc. 1993; 25: 669-672.
71.- Radovancevic B, Birovljev S, Frazier OH. Treating cardiac allograff rejection. Present approach-analysis of 100 consecutive patients. J Heart Transplant 1990; 9: 288-292.
72.- Pham SM, Armitage JM, Kormos RL. Reversal of rejection with FK506 in cardiac transplant recipients. J Heart Lung Transplant 1995; 14: 61-69.
73.- Wiesner RH, Ludwing J, Krom RA, Steers JL,Corayko MH, Gores GJ, Hay JE. Treatment of early cellular rejection following liver transplantation with intravenous methylprednisolone. Transplantation, 1994; 58: 1053-1056.
74.- Emond JC, Thistlethwaite JR, Baker A. Rejection in liver allograft recipients: clinical characterization and management. Clin Transplant 1987;1:143-150.
75.- Jordan ML, Shapiro R, Vivas CA. FK506 rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Trasplantation 1994; 57: 860-865.
76.- Naimark DMJ. Cole E. Determinants of long-trem renal allograft survival. Transplant Rev 1994; 8: 93-113.
77.-Starzl TE. Cell migration and chimerism. A uniflyng concept in transplantation with particular reference to HLA matching and tolerance induction. Transplant Proc 1993; 25: 8-12.
78.- Nisco S, Vriens P, Hoyt G, Lyu S, Farfan F, Pouletty P, Krensky AM, Clayberger C. Induction of allograft tolerance by an HLA class-I-derived peptide and ciclosporine A. J Immunol 1994; 152: 3786-3792.
79.- Ghobrial R, Hamashima T, Stepkowski SM, Kahan BD. Both membrane-bound and soluble truncated RT1.Aa class Y major histocompatibility molecule induce the alloimmune response. Transplantation 1995; 60: 602-610.
80.-Hutchinson IV, Morris PJ. The role of major and minor histocompatibility antigens in active enhancement of rat kidney allografts survival by blood transfusion. Transplantation 1986; 41: 166-170.